Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 3, 2006, Pages 799-805

  Teichman, Sam L ^a   Neale, Ann ^a   Lawrence, Betty ^b   Gagnon, Catherine ^b   Castaigne, Jean Paul ^b   Frohman, Lawrence A ^c  

^a WinPharm Associates   (United States)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CJC 1295; DRUG AFFINITY COMPLEX GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR DERIVATIVE; LONG ACTING DRUG; PLACEBO; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; FLUSHING; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HEADACHE; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HUMAN; HYPOTENSION; INJECTION SITE REACTION; MALE; MOTOR DYSFUNCTION; MULTIPLE DRUG DOSE; MUSCLE SPASM; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SOMATOMEDIN C BLOOD LEVEL;

ADULT; DOUBLE-BLIND METHOD; GROWTH HORMONE-RELEASING HORMONE; HUMAN GROWTH HORMONE; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; PEPTIDE FRAGMENTS; PLACEBOS; REFERENCE VALUES;

EID: 33644832169     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-1536     Document Type: Article

References (14)

1. Raben MS 1958 Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab 18:901-903
2. Brain C, Hindmarsh PC, Pringle PJ, Brook CGD 1989 Use of continuous subcutaneous growth hormone-releasing hormone (GHRH (1-29)NH2) infusions to augment growth hormone secretion and to promote growth. Acta Paediatr Scand 78:109-113
3. Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S 1996 Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab 81:1189-1196
4. Koutkia P, Canavan B, Breu J, Torriani M, Kissko J, Grinspoon S 2004 Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. JAMA 292:210-218
5. Frohman LA, Downs TR, Williams TC, Heimer EP, Pan Y-CE, Felix AM 1986 Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive, N-terminally cleaved product. J Clin Invest 78:906-913
6. Bright GM, Veldhuis JD, Iranmanesh A, Baumann G, Maheshwari H, Lima J 1999 Appraisal of growth hormone (GH) secretion: evaluation of a composite pharmacokinetic model that discriminates multiple components of GH input. J Clin Endocrinol Metab 84:3301-3308
7. Munafo A, Nguyen TXQ, Papasouliotis O, Lécuelle H, Priestley A, Thorner MO 2005 Polyethylene glycol-conugated growth hormone-releasing hormone is long-acting and stimulates GH in healthy young and elderly subjects. Eur J Endocrinol 153:249-256
8. Benquet C, Castaigne J-P, Pham K, Robitaille M, Frohman LA, CJC-1295 (DAC-GRF), a long acting GRF analog, enhances pulsatile GH secretion, increases IGF-I levels, and restores linear growth. Program of the 86th Annual Meeting of The Endocrine Society, New Orleans, LA, 2004, p 491 (Abstract P3-109)
9. Webb CB, Vance ML, Thorner MO, Perisutti G, Thominet J, Rivier J, Vale W, Frohman LA 1984 Plasma growth hormone responses to constant infusions of human pancreatic growth hormone releasing factor: intermittent secretion or response attenuation. J Clin Invest 74:96-103
10. Vance ML, Kaiser DL, Evans WS, Furlanetto R, Vale W, Rivier J, Thorner MO 1985 Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (l-40). J Clin Invest 75:1584-1590
11. Andersen O, Haugaard SB, Flyvbjerg A, Andersen UB, Orskov H, Madsbad S, Nielsen JO, Iversen J 2004 Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study. Eur J Clin Invest 34:561-568
12. Engelson ES, Glesby MJ, Mendez D, Albu JB, Wang J, Heymsfield SB, Kotler DP 2002 Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquired Immune Defic Syndr 30:379-391
13. Burgess E, Wanke C 2005 Use of recombinant human growth hormone in HIV-associated lipodystrophy. Curr Opin Infect Dis 18:17-24
14. Falutz J, Allas S, Kotler D, Thompson M, Koutkia P, Albu J, Trottier B, Routy J-P, Cote P, Abribat T, Grinspoon S 2005 A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS 19:1279-1287